MedWatch

Leo Pharma poised to market new drug every 2-3 years

Dermatology company Leo Pharma turns its eyes towards 2030 with a new strategy to help cement the group’s position on the skin disease treatment market and to firmly position the company in the US.

Leo Pharma CEO Catherine Mazzacco ays the company's own labs will produce more drug candidates in the following years. | Photo: Leo Pharma / PR

Leo Pharma hits the speeder as the company now plans to shower the market with new treatments for both rare and more common skin diseases.

This is at the core of the pharmaceutical company’s recently announced strategy, which will function as a guideline for the company up until 2030 and position the company for launching new pharmaceutical drugs every second year, if everything goes according to plan.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Latest news

See all jobs